Journal Article

DZNE-2020-06881

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Dementia treatment versus prevention.

Perneczky, R. (First author)DZNE*

2019
Les Laboratoires Servier Neuilly-sur-Seine

This record in other databases:    

Please use a persistent id in citations: doi:10.31887/DCNS.2019.21.1/rperneczky

Abstract: Alzheimer disease (AD) and dementia are becoming increasingly prevalent due to the aging of the global populations. Currently available treatment options, including acetylcholinesterase inhibitors and memantine, only have symptomatic effects and no drugs with disease-modifying properties are available. Research on the amyloid cascade indicates that amyloid-β (Aβ) clearance from the brain may be the main pathophysiological change in late-onset AD and the key driver of neurodegeneration, which ultimately results in progressive cognitive deterioration and dementia. Most new AD drug candidates target different aspects of Aβ clearance, eg, using passive anti-Aβ immunization, but so far, all efforts to develop more effective drugs have failed. In parallel, nonpharmacological prevention trials are being conducted to modify dementia risk associated with known epidemiological risk factors. Some initial results are promising, but replication across independent cohorts remains a challenge.

Keyword(s): Amyloid beta-Peptides: metabolism (MeSH) ; Biomarkers: metabolism (MeSH) ; Clinical Trials as Topic (MeSH) ; Dementia: diagnosis (MeSH) ; Dementia: metabolism (MeSH) ; Dementia: prevention & control (MeSH) ; Dementia: therapy (MeSH) ; Humans (MeSH) ; Treatment Outcome (MeSH)

---

Contributing Institute(s):

1. Clinical Neurodegeneration (AG Levin)

Research Program(s):

1. 344 - Clinical and Health Care Research (POF3-344) (POF3-344)

Appears in the scientific report 2019

---

Database coverage:
; ; ; Clarivate Analytics Master Journal List ; SCOPUS ; Web of Science Core Collection

---